- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03192371
A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children
A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
The clinical basis for the last renewal of the Rabipur license in China was the results from study V49_24 (NCT01680016), an immunogenicity and safety trial conducted in Chinese children (6 to 17 years) and adults (≥51 years), which confirmed the non-inferior immunogenicity of the Zagreb versus the conventional Essen post exposure prophylaxis intramuscular (PEP IM) regimen at Day 15 for both age groups.
At the time of license renewal in 2015, the Chinese health authorities requested that GSK continue to conduct immunogenicity persistence follow-ups for at least 1 year to compare the Zagreb regimen with the Essen regimen in populations under 17 years old.
V49_24E1 is an extension study to meet this request, in which subjects aged 17 years or younger who were immunized in the parent trial V49_24 will be recalled for a blood immunogenicity analysis approximately 4-5 years after the original vaccination.
Opintotyyppi
Vaihe
- Vaihe 4
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Individuals of 6 through 17 years of age on the day of informed consent/assent.
- Individuals who are in good health at the time of entry into the study as determined by medical history, physical examination and clinical judgment of the investigator.
- Individuals who or whose parent(s)/legal guardian(s) have voluntarily given written informed consent on behalf of their child, and adolescents who have provided written assent, after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- Individuals who can comply with study procedures and are available for the duration of follow-up.
Exclusion Criteria:
- A body temperature ≥38°C (axillary) within 3 days of intended study vaccination.
- Known hypersensitivity to gentamycin, known allergies to excipients of Rabipur such as Polygeline, chicken protein, egg products or any other vaccine component.
- Previously received any rabies vaccine or rabies immune globulin.
- Subjects currently receiving or planning to receive antimalarial medications 4 days prior to V1/Day 1 vaccination and until the final vaccination.
- Progressive, unstable or uncontrolled clinical conditions.
- Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
Abnormal function of the immune system resulting from:
- Clinical conditions.
- Systemic administration of corticosteroids for more than 14 consecutive days within 90 days prior to informed consent.
- Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
- Received immunoglobulins or any blood products within 180 days prior to informed consent.
- Received an investigational or non-registered medicinal product within 30 days prior to informed consent.
- Study personnel as an immediate family or household member.
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
- Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 28 days from the study vaccines.
- Children in care: A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed legal guardian.
- If female of childbearing potential and sexually active, refusal to use an "acceptable contraceptive method" for the duration of the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Zagreb 2-1-1 Group
4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
|
Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
Muut nimet:
|
Kokeellinen: Essen 1-1-1-1-1 Group
5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
|
Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Evaluation of immunogenicity in terms of antibody concentrations.
Aikaikkuna: Study days 1, 15, 43, 197 and 393.
|
Immunogenicity is assessed in terms of Geometric Mean Concentration (GMC) of Rabies Virus Neutralizing Antibody (RVNA) concentrations. Comparison between Zagreb and Essen groups will be reported in terms of difference between GMCs. |
Study days 1, 15, 43, 197 and 393.
|
Percentage of subjects with RVNA concentrations ≥ 0.5 IU/mL
Aikaikkuna: Study days 1, 15, 43, 197 and 393.
|
Comparison between Zagreb and Essen groups will be reported in terms of difference between percentages of subjects with RVNA concentrations ≥ 0.5 IU/mL.
|
Study days 1, 15, 43, 197 and 393.
|
All Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to subject withdrawal.
Aikaikkuna: From Day1/Visit 1 through Day 393/Visit 11 (study termination).
|
Only SAEs and unsolicited AEs leading to study withdrawal will be collected. SAEs to be assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of existing hospitalization, result in disability/incapacity, result in congenital anomaly/or birth defect or significant medical event that may not be immediately life threatening or resulting in death or hospitalization but may jeopardize the subject or require intervention to prevent one of the other outcomes listed. An unsolicited AE is an AE that was not solicited using a Subject Diary and that was spontaneously communicated by a subject and/or parent(s)/legal guardian(s) who has signed the informed consent. Potential unsolicited AEs may be medically attended (defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider), or were of concern to the subject and/or parent(s)/legal guardian(s). |
From Day1/Visit 1 through Day 393/Visit 11 (study termination).
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Odotettu)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- 205854
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Virussairaudet
-
U.S. Army Medical Research and Development CommandValmis
-
Provention Bio, Inc.ValmisVirus; Infektio, Coxsackie (virus)Suomi
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute...Valmis
-
Vanderbilt University Medical CenterValmis
-
ModernaTX, Inc.RekrytointiHengitykseen liittyvä synsytiaalinen virusKanada, Yhdysvallat, Yhdistynyt kuningaskunta, Puerto Rico
-
ModernaTX, Inc.Aktiivinen, ei rekrytointiHengitykseen liittyvä synsytiaalinen virusYhdysvallat, Panama
-
ModernaTX, Inc.Aktiivinen, ei rekrytointiHengitykseen liittyvä synsytiaalinen virusYhdysvallat, Espanja, Taiwan, Korean tasavalta, Singapore, Kanada, Belgia, Suomi, Japani, Yhdistynyt kuningaskunta, Chile, Uusi Seelanti, Etelä-Afrikka, Australia, Puerto Rico, Argentiina, Costa Rica, Puola, Bangladesh, Kolu... ja enemmän
-
Sanofi Pasteur, a Sanofi CompanyQuantify ResearchAktiivinen, ei rekrytointiRespiratory Syncytal Virus (RSV)
-
Sinovac Biotech Co., LtdPeruutettuInfektio, virus, enterovirusKiina
-
MedImmune LLCValmisRespiratory Syncytal Virus (RSV)Yhdysvallat
Kliiniset tutkimukset Rabipur
-
CureVacValmis
-
GlaxoSmithKlineAktiivinen, ei rekrytointiVirussairaudetItävalta, Saksa, Sveitsi
-
International Centre for Diarrhoeal Disease Research...RekrytointiAlemmuusoikeudenkäyntiBangladesh
-
Provincial Public Health Office, PhetchabunValmis
-
Synermore Biologics Co., Ltd.Synermore Biologics USA LimitedValmisRaivotautiYhdysvallat, Filippiinit
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; United States Agency for International Development (USAID) ja muut yhteistyökumppanitValmis
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)ValmisPlasmodium FalciparumKenia
-
Yisheng Biopharma (Singapore) Pte. Ltd.Valmis
-
Yisheng Biopharma (Singapore) Pte. Ltd.Duke-NUS Graduate Medical SchoolValmis